Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Bungyo Rate Exceeds 40%for Two Consecutive Months
April 16, 2001
- Developing Anti-AIDS Vaccine to Be Given Top Priority: Merck Company Foundation
April 16, 2001
- Reform of Medical Education Proposed to Promote Patient-centered Healthcare
April 16, 2001
- BUSINESS NEWS IN BRIEF -2-
April 16, 2001
- JPA Starts DispensingError/Incidents Reporting System
April 16, 2001
- Takeda's MRs Supported by Highest Percentage of Physicians
April 16, 2001
- Preventive Effects of Simvastatin on Coronary Events Confirmed: Banyu Symposium
April 16, 2001
- BUSINESS NEWS IN BRIEF -1-
April 16, 2001
- British Gov't Invites Japanese Drug Companies to Invest in UK
April 16, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF
April 16, 2001
- JHSF Report Shows Large Gap between US and Japan in Bio Industry
April 16, 2001
- Lilly's Evista Reduces Risk of Heart Disease: MORE Trial
April 16, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
April 16, 2001
- Kokuho Balance of Payment Records Deficit of \120.8 Bil. in FY1999
April 16, 2001
- Sun Drug, Kawachi Yakuhin to Remain Highly Profitable: Nomura Report
April 16, 2001
- Grand Design for Social Security Reform Announced by Gov't, Ruling Coalition
April 16, 2001
- Jovi, Wing to Merge on October 1
April 16, 2001
- 15 New Active Ingredients Including Gemzar, Zyvox Approved
April 16, 2001
- Kirin-do: Double-digit Increases in Sales, Profits
April 16, 2001
- Criteria for Disclosure, Non-disclosure Published
April 16, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…